Healthcare / BiotechnologyNasdaqCM
$4.19
-0.14 (-3.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-104.8M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$368M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-366.2%
↓Gross Margin
82.9%
↑Debt/Equity
1.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-475.9%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.9M · net income $-209.5M · FCF $-147.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $30.9M | $30.9M | $10.0M | — | $2.6M | $2.1M | $88.5M | $17.5M | $26.7M | — | — | — | — | — | — | — |
| Net Income | $-209.5M | $-209.5M | $-130.6M | $-87.4M | $-73.8M | $-71.2M | $-67.7M | $-149.2M | $-72.4M | $-67.8M | $-36.4M | $-57.9M | $-53.4M | $-41.2M | $-32.0M | $-13.7M |
| EBITDA | $-207.6M | $-207.6M | $-125.9M | $-83.2M | $-71.6M | — | — | — | — | — | $-36.3M | $-57.4M | $-53.2M | $-41.2M | $-32.0M | $-13.6M |
| EPS | — | — | -3.66 | -3.96 | -4.57 | -4.90 | -5.28 | -24.00 | -16.44 | -21.12 | -11.88 | — | — | — | — | — |
| Gross Margin | 82.9% | 82.9% | 100.0% | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -550.3% | -550.3% | -1149.6% | — | -2809.6% | -2991.2% | -55.8% | -758.1% | -354.8% | — | — | — | — | — | — | — |
| Net Margin | -677.6% | -677.6% | -1306.4% | — | -2843.3% | -3468.1% | -76.5% | -854.8% | -271.1% | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 1.52 | 1.52 | -1.46 | 0.72 | 0.57 | — | — | — | — | 0.26 | — | — | — | — | — | — |
| Current Ratio | 3.04 | 3.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-147.1M | $-147.1M | $-104.8M | $-86.5M | $-63.7M | $-53.7M | $-33.5M | $-138.5M | $-76.0M | — | $-29.5M | $-45.8M | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | -366.2% | -366.2% | 452.1% | -152.3% | -155.8% | -81.3% | -58.8% | -2079.9% | -58.3% | -117.5% | -50.4% | -56.5% | -60.1% | -35.1% | -35.4% | 107.2% |
| Valuation | ||||||||||||||||
| P/B | 5.69 | 5.69 | — | 3.26 | 1.92 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 209.1% | 209.1% | — | — | — | -97.7% | 407.1% | -34.7% | — | — | — | — | — | — | — | — |
| EPS Growth | — | — | 7.6% | 13.3% | — | 7.2% | 78.0% | -46.0% | 22.2% | -77.8% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.66 → n/d
Residual
-44.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.